Mounjaro

What is Mounjaro and how does it work?

Mounjaro is a prescription medicine containing tirzepatide, developed by Eli Lilly. It activates two receptors, GIP and GLP-1, involved in appetite and blood glucose regulation. For people with an appropriate medical indication, it can support treatment of type 2 diabetes or weight management alongside changes to diet and physical activity.

Tirzepatide is one molecule acting on two pathways, rather than a mixture of two hormones. It can reduce hunger, help people feel full sooner and increase insulin release when glucose is high. It also slows stomach emptying, with this effect strongest early in treatment and diminishing over time.

It is not insulin, and it does not dissolve fat in a selected body area. A useful treatment plan considers health benefits, nutrition, side effects and the ability to continue care, rather than simply aiming for the fastest weight loss.

Is Mounjaro approved in Thailand?

The Thai FDA record reviewed for MOUNJARO 7.5 MG KWIKPEN, registration 1C 42/67 (NC), shows an active registration and classifies that product as a special-controlled medicine. The record was updated on 16 June 2026. It lists type 2 diabetes treatment and adult weight management with dietary calorie reduction and increased physical activity.

For diabetes, that record describes use alone when metformin is unsuitable because of intolerance or a contraindication, or alongside other diabetes medicines. Its weight-management indication covers adults with obesity, or overweight with at least one related condition. These are separate reasons for treatment: weight-management eligibility does not determine a person’s entire diabetes care plan.

This is a check of one specific registered presentation, not confirmation that every strength, pen or vial has an identical Thai label. The exact product name, strength, presentation and Thai prescribing information must be checked for the product being considered. See the Thai FDA product record (Thai).

Why do overseas websites describe different uses?

Brand indications vary by country. In the EU, Mounjaro has diabetes and weight-management indications. The current US Mounjaro label covers type 2 diabetes and reduction of major cardiovascular-event risk in high-risk adults with type 2 diabetes; Zepbound is the US tirzepatide brand with a weight-management indication.

An overseas approval does not establish the approved use of a particular Thai product. The safety information below draws on current international regulatory documents; treatment in Thailand must follow the applicable local product information and medical assessment.

Who may be eligible, including people without diabetes?

Having diabetes is not a prerequisite for adult weight-management treatment. Information published by Zuellig Pharma, the Thai marketing authorisation holder, describes the following weight-management criteria:

• BMI of 30 kg/m² or above; or
• BMI of 27 to below 30 kg/m² with at least one weight-related condition, such as high blood pressure, abnormal blood lipids, obstructive sleep apnoea, cardiovascular disease, prediabetes or type 2 diabetes.

BMI is weight in kilograms divided by height in metres squared. It is a starting point, not an automatic prescription: the doctor also considers weight history, related illness, risks and treatment goals.

Asian BMI risk categories should not be substituted for a medicine’s prescribing criteria. Someone at a healthy weight who wants to lose a few kilograms for an event may have no medical indication and could face more risk than benefit. This page concerns adult weight management, not a treatment plan for children or teenagers.

How much weight loss is realistic?

In SURMOUNT-1, 2,539 adults with obesity, or overweight and a weight-related complication, were studied for 72 weeks. People with diabetes were excluded. Average weight reduction across the tirzepatide groups was approximately 15.0% to 20.9%, compared with 3.1% with placebo; all groups received diet and activity support.

These are trial averages, not a promised minimum or a reason to seek the highest strength. Participants started at an average weight of 104.8 kg and BMI of 38, so the results cannot be directly applied to a normal-weight person or assumed to predict an individual’s response. Health conditions, tolerability and treatment continuity matter.

How much should you lose in the first month?

There is no reliable kilogram target that applies to everyone. A 72-week result cannot be divided into monthly targets, and the first stage of care includes assessing tolerability. Changes in body water and bowel habits can also affect the scale. Compare progress with an agreed clinical plan rather than another person’s before-and-after photographs.

Does a weight plateau mean the medicine has stopped working?

Not necessarily. A follow-up analysis of SURMOUNT-1 and SURMOUNT-4 found that weight loss commonly slowed and reached a plateau during treatment. A clinician can review the longer-term trend, nutrition, activity and other health benefits before deciding whether a change is appropriate. A few unchanged weigh-ins are not a reason to adjust treatment yourself.

How does it compare with Wegovy, Ozempic and Saxenda?

The brand, active ingredient and approved purpose are separate considerations. This overview identifies the medicines; it does not mean their Thai indications, strengths or treatment plans are interchangeable.

SURMOUNT-5 directly compared tirzepatide and semaglutide in 751 adults with obesity but without type 2 diabetes. At 72 weeks, average weight reductions were 20.2% and 13.7%, respectively. This was an open-label trial using the maximum tolerated study treatments, so it does not establish that every tirzepatide strength is better for every patient.

The choice should account for medical history, tolerability, cost and sustainable follow-up. Other options include structured nutrition and behavioural support, different medicines where appropriate, or specialist assessment for metabolic or bariatric surgery in eligible patients. Medicines should not be combined or substituted without the treating clinician’s review.

What should a medical assessment cover?

Assessment starts with the health problem and treatment goal, not with choosing a pen strength. The following are general care principles; they are not a fixed testing package or a description of a guaranteed clinic process.

• Relevant history: weight changes, previous treatment, eating patterns, sleep, medical conditions, allergies, pregnancy plans and all medicines or supplements being used.
• Baseline health: weight, height, BMI, waist measurement and blood pressure, with blood tests or other investigations when clinically indicated.
• A shared plan: expected benefits, meaningful goals, risks, alternatives, likely ongoing costs and how progress will be reviewed.
• Continuity: who will oversee treatment, how to report side effects and how care will be coordinated if another doctor manages diabetes or other conditions.

For foreign residents already receiving care overseas, a new consultation should establish who is responsible for ongoing decisions. Previous use abroad does not replace local assessment or confirm that an identically named product has the same presentation.

Who should avoid it or needs extra caution?

A previous serious allergic reaction to tirzepatide or another ingredient rules out using that product. Other conditions require individual assessment and are not all equivalent to an absolute contraindication.

• Previous pancreatitis or gallbladder disease: the doctor needs to consider the history and any current abdominal symptoms.
• Severe delayed stomach emptying or other serious digestive problems: treatment can be difficult to tolerate. The US label does not recommend Mounjaro for severe gastroparesis.
• Kidney disease or vulnerability to dehydration: vomiting and diarrhoea can worsen kidney function, particularly when fluid intake is poor.
• Diabetic eye disease: changes in glucose control may require closer retinal follow-up.

What does the thyroid cancer warning mean?

The US label contraindicates Mounjaro in people with a personal or family history of medullary thyroid carcinoma (MTC), or multiple endocrine neoplasia syndrome type 2 (MEN 2). Its warning follows thyroid C-cell tumours in animal studies; whether tirzepatide causes these tumours in humans is unknown.

This is not the same as saying every thyroid condition has the same risk. Give the doctor the specific diagnosis and family history so the relevant Thai label and clinical circumstances can be assessed. A neck lump, persistent hoarseness or difficulty swallowing warrants medical review.

Other medicines, surgery and endoscopy

Insulin and sulfonylureas can increase the risk of low blood glucose when used with tirzepatide. The treating team may need to revise the diabetes plan and glucose monitoring. Tirzepatide is not a substitute for insulin, and insulin should not be stopped or reduced independently.

Slower stomach emptying can affect the absorption of some oral medicines. Drugs requiring close control of their effect, such as warfarin, deserve particular attention. The medication review should also identify other tirzepatide, GLP-1 or weight-loss products to prevent inappropriate overlap.

Before surgery, endoscopy or any procedure involving general anaesthesia or deep sedation, tell the procedural team that you use tirzepatide. Food may remain in the stomach despite fasting, increasing the risk of aspiration into the lungs. The team should give an individual plan; there is no single stop-before-procedure interval to apply yourself.

Pregnancy, contraception and breastfeeding

Tirzepatide should not be used for weight loss during pregnancy. If pregnancy occurs or is suspected, contact the prescriber promptly to stop treatment and arrange appropriate care, including an alternative glucose-management plan if needed.

For planned pregnancy, the European product information advises stopping tirzepatide at least one month beforehand. Discuss this in advance with the treating doctor rather than stopping necessary diabetes care without a replacement plan.

Oral contraception may be less effective. The US label and UK safety advice recommend switching to a non-oral method or adding a barrier method, such as condoms, for four weeks after starting tirzepatide and four weeks after each dose increase. This is a contraceptive precaution, not a schedule for changing treatment.

Breastfeeding needs an individual assessment. Current EU and US product information reports very low or undetectable milk levels in a single-dose study, but evidence on infant outcomes and milk production or nutrition remains limited. Advice differs between countries; discuss the applicable Thai label, the mother’s clinical need and the baby’s health before starting or continuing.

Which side effects need medical attention?

Nausea, diarrhoea, vomiting, constipation, reduced appetite, indigestion and abdominal discomfort are common concerns. Digestive symptoms may be more noticeable early in treatment or after a treatment change. Symptoms that prevent adequate eating or drinking should not be dismissed as proof that the medicine is working well.

For mild nausea or fullness, smaller meals, slower eating and avoiding foods that trigger symptoms may help. Fluid intake should suit the person’s health: anyone with a prescribed fluid restriction should follow that plan. Persistent symptoms need review rather than self-adjustment of the medicine.

Sweating, shaking, palpitations or confusion can signal low blood glucose, especially with certain diabetes medicines. The care team should explain an individual response plan. In Thailand, call 1669 for a medical emergency.

What should be monitored during treatment?

Follow-up should consider weight and waist trends, relevant blood pressure or glucose changes, side effects, hydration and whether daily activities remain manageable. Tests and appointment frequency depend on clinical need; a standard package is not suitable for everyone.

Reduced hunger should still leave room for adequate nutrition. A sustainable plan includes appropriate protein and varied foods, together with physical activity and resistance exercise suited to the person’s health and mobility. Dietary advice may need adjusting for kidney disease or other conditions.

Very limited intake, weakness or rapid weight loss accompanied by poor wellbeing calls for reassessment. If treatment is interrupted, contact the prescriber for advice based on the exact product and history rather than resuming a previous plan or compensating independently.

Will weight return after stopping, and is treatment lifelong?

Weight regain can occur after stopping, even when someone continues making an effort with food and activity. Obesity often needs long-term care; regain should not be treated simply as a failure of willpower. There is no single duration appropriate for everyone.

In SURMOUNT-4, participants first received tirzepatide for 36 weeks. Those who completed this stage were then assigned to continue treatment or switch to placebo for 52 weeks. The placebo-switch group gained an average of 14.0% relative to their weight at week 36, while the continuing group lost a further 5.5%.

That is not a 14 kg gain or a 14% increase from the original starting weight. The withdrawal study supports planning for maintenance, but its selected participants do not represent every new user and it does not prove that everyone must remain on treatment for life.

Before starting, consider what would happen if side effects, cost, travel or changing health needs made continuation difficult. The clinician can review ongoing benefit and alternatives, with nutritional and behavioural support after stopping. A promise that tapering will prevent all regain is not supported by this study.

What prices does Smooth Clinic publish?

The Smooth Clinic price catalogue (Thai) lists the following Mounjaro strengths and amounts, checked on 15 October 2026, Thailand time. They are published catalogue figures, not a recommendation to select a strength.

The card labels strength in milligrams but does not specify whether the price is per pen, box, administration or treatment period. It also does not establish the pack quantity or whether consultation, tests, equipment or follow-up are included. A monthly cost or four-week supply cannot be inferred from these amounts.

For budgeting, ask for the total cost of the clinically appropriate plan and its inclusions. A higher strength is not automatically more suitable or better value. Published prices do not establish current stock, and the actual details need confirmation before making travel or treatment arrangements.

How should the product and provider be checked?

Medication safety involves both the product and the care around it. Verification should cover the exact Thai registration, product name and strength, batch and expiry information, intact packaging, traceable supply and appropriate temperature control. A photograph of a box or pen cannot establish authenticity or its storage history.

A suitable healthcare provider should be able to explain the medical indication, alternatives, important risks and arrangements for follow-up or referral. Check the practitioner’s professional registration and the facility’s licensing rather than relying only on testimonials or a promotional price. An authentic medicine can still be unsuitable for a particular patient.

Overseas pens and packaging should not be assumed to match the Thai presentation. Product-specific handling questions belong with the treating professional and the supplied instructions, rather than a demonstration for a different device found online.

Planning a consultation in Bangkok

Use Smooth Clinic’s contact details to ask about a medical consultation, its fee and the arrangements for follow-up. The published address is on the second floor of Times Square, Sukhumvit Road, near Asok BTS and Sukhumvit MRT; confirm the appointment and directions before travelling.

If you need the consultation or written advice in English, ask about language support in advance. Foreign residents and short-stay visitors should also clarify how care would continue when travelling or returning home. Do not assume a brief visit provides the follow-up needed for a longer-term treatment.

A consultation is an opportunity to decide whether medication is appropriate. It does not guarantee a prescription, a requested strength or any particular weight-loss result.

Sources and further information

These sources distinguish local registration, clinical trials and international safety guidance. Information is educational and does not replace an individual medical assessment or the instructions for the specific product.

• Zuellig Pharma: Mounjaro introduction and adult weight-management criteria in Thailand.
• European Medicines Agency: Mounjaro product information.
• Eli Lilly: US Mounjaro prescribing information, revised August 2026; US Zepbound prescribing information.
• Clinical trials: SURMOUNT-1, SURMOUNT-5, SURMOUNT-4 and the weight-plateau analysis.
• European Medicines Agency product overviews: Wegovy, Ozempic and Saxenda.
• UK MHRA: GLP-1 medicines, pregnancy and contraception; anaesthesia and aspiration precautions; pancreatitis warning.
• MedlinePlus: tirzepatide safety information. NICE: general principles of weight-management medicines and surgery.